WO2006102533A3 - Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates - Google Patents

Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates Download PDF

Info

Publication number
WO2006102533A3
WO2006102533A3 PCT/US2006/010638 US2006010638W WO2006102533A3 WO 2006102533 A3 WO2006102533 A3 WO 2006102533A3 US 2006010638 W US2006010638 W US 2006010638W WO 2006102533 A3 WO2006102533 A3 WO 2006102533A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleoside
lipid
methods
pharmaceutically active
based formulation
Prior art date
Application number
PCT/US2006/010638
Other languages
French (fr)
Other versions
WO2006102533A2 (en
Inventor
Jia-Ai Zhang
Sydney Ugwu
Lan Ma
Moghis U Ahmad
Shoukath M Ali
Abdul R Khan
Imran Ahmad
Original Assignee
Neopharm Inc
Jia-Ai Zhang
Sydney Ugwu
Lan Ma
Moghis U Ahmad
Shoukath M Ali
Abdul R Khan
Imran Ahmad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharm Inc, Jia-Ai Zhang, Sydney Ugwu, Lan Ma, Moghis U Ahmad, Shoukath M Ali, Abdul R Khan, Imran Ahmad filed Critical Neopharm Inc
Publication of WO2006102533A2 publication Critical patent/WO2006102533A2/en
Publication of WO2006102533A3 publication Critical patent/WO2006102533A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel formulations of nucleoside-lipid conjugates, the methods of preparing them and the methods for administering them are provided. More particularly, methods for making liposomal formulations of nucleoside-cardiolipin and analogues thereof are provided. By encapsulating nucleoside prodrugs, drugs are protected from degradation, thereby extending the drugs' plasma half-life and intracellular release. In addition, compositions that demonstrate greater efficacy and higher cytotoxicity are produced. Accordingly, nucleoside-lipid conjugates that demonstrate greater in-vitro and in-vivo activity are produced.
PCT/US2006/010638 2005-03-23 2006-03-23 Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates WO2006102533A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66460105P 2005-03-23 2005-03-23
US60/664,601 2005-03-23

Publications (2)

Publication Number Publication Date
WO2006102533A2 WO2006102533A2 (en) 2006-09-28
WO2006102533A3 true WO2006102533A3 (en) 2007-12-13

Family

ID=37024639

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/010638 WO2006102533A2 (en) 2005-03-23 2006-03-23 Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates

Country Status (1)

Country Link
WO (1) WO2006102533A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20053519L (en) * 2005-07-18 2007-01-19 Thia Medica As Use of compounds comprising fatty acids
WO2011084610A1 (en) * 2009-12-16 2011-07-14 Children Medical Center Corporation Liposomes for preventing the spread of hiv
CN102144981B (en) * 2011-04-07 2013-02-27 海南锦瑞制药股份有限公司 Gemcitabine hydrochloride lyophilized powder injection and preparation method thereof
EP2815241A2 (en) * 2012-02-15 2014-12-24 Basf Se Means and methods for assessing bone disorders
KR102363946B1 (en) 2015-03-06 2022-02-17 아테아 파마슈티컬즈, 인크. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for the treatment of HCV
EP4088725A1 (en) 2016-09-07 2022-11-16 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family
UA127407C2 (en) 2017-02-01 2023-08-16 Атеа Фармасеутікалс, Інк. Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
JP2021521118A (en) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド Treatment of HCV-infected patients with cirrhosis
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017944A1 (en) * 2002-08-23 2004-03-04 Neopharm, Inc. Liposomal gemcitabine compositions for better drug delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017944A1 (en) * 2002-08-23 2004-03-04 Neopharm, Inc. Liposomal gemcitabine compositions for better drug delivery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALI ET AL.: "Synthesis and biological evaluation of gemicitabine-lipid conjugate (NEO6002)", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, 2005, pages 2571 - 2574, XP004866838 *
IMMORDINO ET AL.: "Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing liposomes containing lipophilic gemicitabine prodrugs", JOURNAL OF CONTROLLED RELEASE, vol. 100, no. 3, 2004, pages 331 - 346, XP004656456 *

Also Published As

Publication number Publication date
WO2006102533A2 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
WO2006102533A3 (en) Pharmaceutically active lipid-based formulation of nucleoside-lipid conjugates
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2002074247A8 (en) Pharmaceutical formulations for sustained release
WO2007022255A3 (en) Pharmaceutical formulations for sustained release
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2006124047A3 (en) Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
ZA200709251B (en) Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
HK1096034A1 (en) A solid dosage form comprising a fibrate
WO2006078811A3 (en) Pharmaceutical formulations and methods of use
WO2006084164A8 (en) Gastric retention and controlled release delivery system
CA3094580A1 (en) Oral formulations of cytidine analogs and methods of use thereof
PL1792927T3 (en) Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
WO2006099169A3 (en) Novel liposome compositions
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
WO2007117550A3 (en) Methods for coacervation induced liposomal encapsulation and formulations thereof
WO2007047948A3 (en) Intranasal administration of rapid acting insulin
WO2007009806A3 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
WO2006101882A3 (en) Medicament delivery formulations, devices and methods
AU2003270255A1 (en) Fast releasing, solid administration form for oral application of active ingredients which are hard to dissolve
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
MY143549A (en) Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases
EP2308479A3 (en) Compounds and compositions for delivering active agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06739437

Country of ref document: EP

Kind code of ref document: A2